Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Non-cash Items (2019 - 2025)

Tg Therapeutics has reported Non-cash Items over the past 7 years, most recently at $96.7 million for Q4 2025.

  • Quarterly results put Non-cash Items at $96.7 million for Q4 2025, down 6.77% from a year ago — trailing twelve months through Dec 2025 was $96.7 million (down 6.77% YoY), and the annual figure for FY2025 was $96.7 million, down 6.77%.
  • Non-cash Items for Q4 2025 was $96.7 million at Tg Therapeutics, down from $103.7 million in the prior quarter.
  • Over the last five years, Non-cash Items for TGTX hit a ceiling of $102.5 billion in Q1 2021 and a floor of $25.1 million in Q4 2022.
  • Median Non-cash Items over the past 5 years was $72.1 million (2023), compared with a mean of $17.1 billion.
  • Peak annual rise in Non-cash Items hit 1020.12% in 2021, while the deepest fall reached 74.45% in 2021.
  • Tg Therapeutics' Non-cash Items stood at $29.5 million in 2021, then fell by 15.04% to $25.1 million in 2022, then skyrocketed by 89.94% to $47.6 million in 2023, then soared by 117.81% to $103.7 million in 2024, then fell by 6.77% to $96.7 million in 2025.
  • The last three reported values for Non-cash Items were $96.7 million (Q4 2025), $103.7 million (Q4 2024), and $47.6 million (Q4 2023) per Business Quant data.